Sands Capital's Board Representation Ends Following Director's Passing
ALMR sits 34% above its 52-week low of $18.845.
Summary
Sands Capital, a 6.1% shareholder, no longer has a representative on Alamar Biosciences' board of directors following the passing of their Executive Managing Partner, Ian Ratcliffe.
Key Events · Ownership and Investor Activity · ALMR
-
Director Departure
Ian Ratcliffe, an Executive Managing Partner of Sands Capital, has passed away and ceased to serve on Alamar Biosciences' board of directors as of July 5, 2026.
-
Loss of Board Representation
Sands Capital, a significant 6.1% beneficial owner, no longer has direct representation on Alamar Biosciences' board of directors.
-
No Intent for New Representation
The reporting persons (Sands Capital) do not currently intend to seek new board representation.
-
Ownership Unchanged
Sands Capital continues to beneficially own 4,230,926 shares, representing approximately 6.1% of the company's common stock.
Analysis · ALMR · Industrial Applications And Services
This amendment to Sands Capital's Schedule 13D reports that Ian Ratcliffe, an Executive Managing Partner of Sands Capital, has ceased to serve on Alamar Biosciences' board of directors following his passing. This means Sands Capital, a significant 6.1% shareholder, no longer has direct representation on the company's board and does not currently intend to seek new representation. This alters the governance structure and the direct influence of a major institutional investor.
At the time of this filing, ALMR was trading at $25.23 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $18.85 to $28.68. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.